Erlotinib - Generic Drug Details
✉ Email this page to a colleague
US Patents and Regulatory Information for erlotinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Rx | ERLOTINIB HYDROCHLORIDE | erlotinib hydrochloride | TABLET;ORAL | 203843-001 | Sep 13, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm | ERLOTINIB HYDROCHLORIDE | erlotinib hydrochloride | TABLET;ORAL | 210300-001 | Nov 5, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Usa Inc | ERLOTINIB HYDROCHLORIDE | erlotinib hydrochloride | TABLET;ORAL | 091059-002 | Aug 28, 2015 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

